Cara Therapeutics (NASDAQ:CARA) Coverage Initiated by Analysts at StockNews.com

StockNews.com began coverage on shares of Cara Therapeutics (NASDAQ:CARA) in a report published on Tuesday morning. The brokerage issued a sell rating on the biopharmaceutical company’s stock.

Cara Therapeutics Stock Performance

Shares of Cara Therapeutics stock opened at $0.34 on Tuesday. Cara Therapeutics has a 52-week low of $0.24 and a 52-week high of $1.31. The company’s 50 day moving average price is $0.29 and its 200-day moving average price is $0.41. The stock has a market capitalization of $18.64 million, a price-to-earnings ratio of -0.17 and a beta of 0.68.

Cara Therapeutics (NASDAQ:CARA) last announced its quarterly earnings results on Wednesday, August 14th. The biopharmaceutical company reported ($0.37) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.27) by ($0.10). The firm had revenue of $0.99 million during the quarter, compared to the consensus estimate of $1.26 million. Cara Therapeutics had a negative return on equity of 241.31% and a negative net margin of 1,010.20%. As a group, equities research analysts forecast that Cara Therapeutics will post -1.24 earnings per share for the current fiscal year.

Institutional Trading of Cara Therapeutics

An institutional investor recently bought a new position in Cara Therapeutics stock. Marquette Asset Management LLC acquired a new position in Cara Therapeutics, Inc. (NASDAQ:CARA) in the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 94,238 shares of the biopharmaceutical company’s stock, valued at approximately $86,000. Marquette Asset Management LLC owned 0.17% of Cara Therapeutics at the end of the most recent reporting period. 44.66% of the stock is owned by institutional investors.

About Cara Therapeutics

Cara Therapeutics, Inc, a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States. The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.